NCT06596252 - Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | Biotech Hunter

Enrollment

308

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions

Eosinophilic Esophagitis

Interventions

DRUG

Budesonide

Twice daily intake of the tablet 30 min after a meal

Trial Locations (12)

13700

RECRUITING

Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso

44195

NOT_YET_RECRUITING

Dr. Falk Investigational Site, Cleveland

55905

RECRUITING

Dr. Falk Investigational Site, Rochester

70072

RECRUITING

Dr. Falk Investigational Site, Marrero

70363

RECRUITING

Dr. Falk Investigational Site, Houma

78550

RECRUITING

Dr. Falk Investigational Site, Harlingen

90717

RECRUITING

Dr. Falk Investigational Site, Lomita

92037

RECRUITING

Dr. Falk Investigational Site, La Jolla

02111

RECRUITING

Dr. Falk Investigational Site, Boston

07728

RECRUITING

Dr. Falk Investigational Site, Freehold

08527

RECRUITING

Dr. Falk Investigational Site, Jackson

27599-7080

RECRUITING

Dr. Falk Investigational Site, Chapel Hill